BBS Faculty Member - Marsha Moses

Marsha Moses

Julia Dyckman Andrus Professor, Harvard Medical School
Director, Vascular Biology Program, Children's Hospital Boston
Department of Surgery


Boston Children's Hospital
Karp Family Research Laboratories 12.129
300 Longwood Ave.
Boston, MA 02115-5737
Tel: 617-919-2207
Fax: 617-730-4655
Email: marsha.moses@childrens.harvard.edu



Dr. Marsha A. Moses is the Julia Dyckman Andrus Professor at Harvard Medical School and the Director of the Vascular Biology Program at Boston Children's Hospital. She has had a long-standing interest in identifying and characterizing the biochemical and molecular mechanisms that underlie the regulation of tumor growth and progression. Dr. Moses and her laboratory have discovered a number of angiogenesis inhibitors that function at both the transcriptional and translational level, some of which are being developed for clinical use.

Named a pioneer in the exciting field of Biomarker Medicine by the
Journal of the National Cancer Institute, Dr. Moses established a Proteomics Initiative in her laboratory that has led to the discovery of panels of noninvasive urinary cancer biomarkers that can predict disease status and stage in cancer patients and that are sensitive and specific markers of disease progression and therapeutic efficacy of cancer drugs. A number of these urine tests have been made commercially available. These diagnostics and therapeutics are included in Dr. Moses’ significant patent portfolio which is composed of both US and foreign patents.

About Marsha A. Moses, Ph.D.

Dr. Moses received a Ph.D. in Biochemistry from Boston University and completed a National Institutes of Health postdoctoral fellowship at Boston Children's Hospital and MIT. She is the recipient of a number of NIH and foundation grants and awards. Dr. Moses has been recognized with both of Harvard Medical School's mentoring awards, the A. Clifford Barger Mentoring Award (2003) and the Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty (2009). In 2013, she received the Honorary Member Award from the Association of Women Surgeons of the American College of Surgeons. Dr. Moses was elected to the I
nstitute of Medicine of the National Academies of the United States in 2008 and to the National Academy of Inventors in 2013.



Last Update: 3/26/2014



Publications

For a complete listing of publications click here.

 


 

Jia D, Hasso SM, Chan J, D’Amore, Zurakowski D, Rodig SJ, Moses MA. Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood. 2012 Dec 3; Epub ahead of print. PMCID: In Process.

Roy R, Rodig S, Bielenberg D, Zurakowski D, Moses MA. ADAM12 transmembrane and secreted isoforms promote breast tumor growth and metastasis. J Biol Chem 2011 Apr 14; Epub ahead of print. PMCID: In Process.

Fernandez CA, Roy R, Lee S, Yang J, Panigrahy D, Van Vliet KJ, Moses MA. The anti-angiogenic peptide, Loop 6, binds IGF-IR. J Biol Chem. 2010 Oct 12; Epub ahead of print. PMID: 20940305

Yang J., Bielenberg D.R., Rodig S.J., Doiron R., Clifton M.C., Kung A.L., Strong R.K., Zurakowski D., Moses M.A. (2009) Lipocalin 2 promotes breast cancer progression. PNAS, 106(10):3913-8.

Harper J., Yan L., Louriero R., Wu I., Fang J., D'Amore P., Moses M.A. (2007) Repression of VEGF expression by the zinc finger transcription factor ZNF24. Cancer Res., 67(18):8736-41.

Pories S.E., Zurakowski D., Roy R., Lamb C.C., Raza S., Exarhopoulos A., Scheib R.G., Schumer S., Lenahan C., Borges V., Louis G.W., Anand A., Isakovich N., Hirschfield-Bartek J., Wewer U., Lotz M.M., Moses M.A. (2008) Urinary metalloproteinases: noninvasive biomarkers of breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev., 17(5):1034-42.

Smith E.R., Manfredi M., Scott R.M., Black P., Moses M.A. (2007) A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery, 60(6):E1148-9.



© 2014 by the President and Fellows of Harvard College